DelveInsight’s Complement 3 Glomerulopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement 3 glomerulopathy drugs, market share of ...
Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...
MedPage Today on MSN
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis
The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback